Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-100
SponsorXiangtan Central Hospital
About this trial
The primary objective of this study is to investigate the hemoglobin change and association between hemoglobin change and readmissions due to heart failure, and all-cause death in patients with heart failure treated with dapagliflozin or placebo.
Eligibility criteria
Qualifiers
Male or female between the ages of 18 and 100 years.
Elevated NT-proBNP or BNP levels on admission.
Ejection fraction of 50% or less, and New York Heart Association (NYHA) class II, III, or IV symptoms.
Disqualifiers
Treatment with SGLT2-i during the past 3 months of admission,or previous intolerance of an SGLT2 inhibitor.
Severe (eGFR <30 mL/min/1.73 m² by CKD-EPI), unstable or rapidly progressing renal disease at the time of randomization.
Pregnant or breast feeding female patients.
Trial design
Treatments tested in this trial
- Dapagliflozin
- Placebo
Treatment groups
1,990 Participants
are divided into 2 treatment groupsSponsors and collaborators
Xiangtan Central Hospital
Lead sponsor
Second Xiangya Hospital of Central South University
Collaborator
ZhuZhou Central Hospital
Collaborator
Source ClinicalTrials.gov